Etelcalcetide
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Romosozumab
Monoclonal Antibody · Osteoporosis treatment
Also known as Evenity
Monoclonal AntibodyOsteoporosis treatment
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- EtelcalcetideSevereDatabaseDDInter
Mechanism
Romosozumab is an antibody that inhibits sclerostin. Sclerostin is a protein that blocks osteoblast proliferation by inhibiting the Wnt pathway. By inhibiting sclerostin, romosozumab promotes osteoblast proliferation and bone formation. It also initially suppresses osteoclast activity.
Indications
Treatment of osteoporosispostmenopausal women with osteoporosis
Dosing
- Adult
- range of doses that are generally regarded as being suitable for adults. Complementary and alternative medicine Prescribing unlicensed medicines An increasing amount of information on complementary and alternative medicine is becoming available.…
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Romosozumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team